Status:
UNKNOWN
Interleukin-1 Receptor Antagonist and Insulin Sensitivity
Lead Sponsor:
Radboud University Medical Center
Conditions:
Diabetes Mellitus, Type 2
Insulin Resistance
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Obesity is characterized by continuous low-grade inflammation. This is an important link between obesity and insulin resistance. Results from the investigators' own group of in vitro and in vivo rese...
Detailed Description
The prevalence of obesity is increasing fast. Obesity is one of the most common acquired risk factors for insulin resistance. As a consequence the prevalence of type 2 diabetes mellitus is rising fast...
Eligibility Criteria
Inclusion
- adult subjects with a BMI \> 30 kg/m2
- 3 or more characteristics of the metabolic syndrome
Exclusion
- inability to give informed consent
- age \< 18 years
- known diabetes mellitus
- fasting plasma glucose \> 7,0 mmol/l or HbA1c \> 6,2%
- presence of any medical condition that might interfere with the current study protocol
- immunodeficiency of immunosuppressive treatment
- anti-inflammatory drugs (100 mg of aspirin/day is allowed)
- signs of current infection
- history of recurrent infections
- pregnancy or breast feeding
- liver disease
- renal disease
- neutropenia
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00928876
Start Date
June 1 2009
End Date
July 1 2010
Last Update
December 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabdoud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500 HB